FH-006

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameFH-006
Drug Alias NameFH-006FH006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsCD276 antigen modulators
TargetsEpidermal growth factor receptor erbB1CD276 antigen
Therapy Area/IndicationsSolid tumoursLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co LtdShanghai Fuhong Biomedical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Fuhong Biomedical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A